Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | AOC2 | O75106 | 5/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217002 | 0.82 | MAOA (0.45) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL9935109 | 0.81 | MAOA (0.43) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL295051 | 0.81 | MAOA (0.43) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL3626527 | 0.81 | MAOA (0.43) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL295013 | 0.78 | MAOA (0.41) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL10645704 | 0.78 | MAOA (0.41) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL9773035 | 0.78 | MAOA (0.41) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL8972473 | 0.77 | MAOA (0.39) | MAOAMAOBGAANPSR1 | |
| SCHEMBL8663951 | 0.75 | AKR1B1 (0.38) | MAOAMAOBGAANPSR1LMNA | |
| SCHEMBL294713 | 0.75 | MAOA (0.38) | MAOAMAOBGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425008-B1 | USE OF SUBSTITUTED AMINOMETHYL CHROMANS IN THE TREATMENT OF SIDE EFFECTS OF NEUROLEPTICS | MERCK PATENT GMBH (DE) | 2006-10-04 | — | — | EP | claimed |
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| EP-1863784-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006102958-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-10-05 | — | — | WO | disclosed |
| EP-1067965-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL APOPLEXY AND CRANIOCEREBRAL TRAUMA | BAYER HEALTHCARE AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| EP-1067965-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL APOPLEXY AND CRANIOCEREBRAL TRAUMA | Bayer Aktiengesellschaft (DE) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999029346-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL APOPLEXY AND CRANIOCEREBRAL TRAUMA | BAYER AKTIENGESELLSCHAFT (DE) | 1999-06-17 | — | — | WO | disclosed |
| US-5658941-A | PSYCHOLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| US-5496847-A | ANXIOLYTIC AND ANTIDEPRESSANT | BRISTOL-MYERS SQUIBB CO. (US) | 1996-03-05 | — | — | US | disclosed |
| US-5391570-A | Anxiolytic agents; antidepressants | BRISTOL-MYERS SQUIBB (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0157267-B1 | SUBSTITUTED BENZOPYRANS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1988-11-23 | — | — | EP | disclosed |
| US-4659737-A | Substituted aminomethyl benzopyrans having anti-hypertensive activities | BAYER AKTIENGESELLSCHAFT (DE) | 1987-04-21 | — | — | US | disclosed |
| US-4659737-A | Substituted aminomethyl benzopyrans having anti-hypertensive activities | BAYER AKTIENGESELLSCHAFT (DE) | 1987-04-21 | — | — | US | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0157267-A2 | Substituted benzopyrans, process for their preparation and their use in medicines | BAYER AG (DE) | 1985-10-09 | — | — | EP | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | MAOB, MAOA, AOC3 | MAOA 2/4885MAOB 1/4885GAA 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.